阿戈美拉汀治疗首发抑郁症的临床效果

目的观察阿戈美拉汀治疗首发抑郁症的有效性及安全性。方法将76例首发抑郁症患者按照随机数字表法分为阿戈美拉汀组和氟西汀组各38例,分别以阿戈美拉汀25~50 mg/d和氟西汀20~40 mg/d治疗,两组均治疗6周。分别于治疗前及治疗第1、2、4、6周末采用汉密尔顿抑郁量表17项版(HAMD-17)评定临床疗效,于治疗6周末采用副反应量表(TESS)评定药物的安全性。结果阿戈美拉汀组有效率为86.84%,氟西汀组有效率为84.21%,两组差异无统计学意义(P0.05);在治疗第1、2周末,阿戈美拉汀组HAMD-17总评分及焦虑/躯体化、睡眠障碍因子评分均低于氟西汀组,差异均有统计学意义(P均0.05)。治疗6周末,两组TESS评分比较差异无统计学意义(2.92±2.11)分vs.(3.42±2.13)分,P0.05]。结论阿戈美拉汀对首发抑郁症的疗效较好、安全性较高,尤其适用于伴有焦虑、失眠的抑郁症患者。

Efficacy of agomelatine in treatment for patients with first - episode depression

Objective To observe the efficacy and safety of agomelatine in treatment for patients with first - episode depression. Methods A total of 76 patients with first - episode depression were randomly divided into agomelatine group(38 cases treated with agomelatine 25 ~ 50 mg/ d)and fluoxetine group(38 cases treated with fluoxetine 20 ~ 40 mg/ d)for 6 weeks. The Hamilton Depression Scale - 17 item(HAMD - 17)was used to evaluate the clinical efficacy before treatment and at the 1st ,2nd ,4th and 6th weekend of treatment,and the adverse reactions were assessed with the Treatment Emergent Symptom Scale(TESS)at the 6th weekend of treatment. Results The effective rate of agomelatine group was 86. 84% ,while the fluoxetine group was 84. 21% . There was no statistical significance between the two groups(P > 0. 05). The total score of HAMD - 17,score of anxiety/ somatization and sleep disorder in agomelatine group were lower than those of fluoxetine group at the 1st and 2nd weekend of treatment(P < 0. 05). At the 6th weekend of treatment,there was no significant difference in the TESS scores of the two groups. Conclusion Agomelatine is effective and safe in treatment for first - episode depression,especially suitable for patients with anxiety and insomnia symptoms.